Breaking News

MilliporeSigma Closes Acquisition of Mirus Bio

Adding Mirus Bio’s transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.

Author Image

By: Charlie Sternberg

Associate Editor

MilliporeSigma’s Life Science business has closed its acquisition of Mirus Bio for approximately $600 million following regulatory clearances and the fulfillment of other customary closing conditions.   The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production.   &#8220...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters